Logo image of CYXT

CYXTERA TECHNOLOGIES INC (CYXT) Stock Fundamental Analysis

NASDAQ:CYXT - Nasdaq - US23284C1027 - Common Stock - Currency: USD

0.065  +0.02 (+55.5%)

After market: 0.0595 -0.01 (-8.46%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CYXT. CYXT was compared to 82 industry peers in the IT Services industry. Both the profitability and financial health of CYXT have multiple concerns. CYXT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CYXT had negative earnings in the past year.
CYXT had a positive operating cash flow in the past year.
CYXT had negative earnings in each of the past 5 years.
Of the past 5 years CYXT 4 years had a positive operating cash flow.
CYXT Yearly Net Income VS EBIT VS OCF VS FCFCYXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 -200M -400M

1.2 Ratios

CYXT has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYXT Yearly ROA, ROE, ROICCYXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 -20 -40 -60 -80

1.3 Margins

CYXT has a Gross Margin of 46.37%. This is in the better half of the industry: CYXT outperforms 71.43% of its industry peers.
CYXT's Gross Margin has improved in the last couple of years.
CYXT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.68%
GM growth 5YN/A
CYXT Yearly Profit, Operating, Gross MarginsCYXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 20 -20 40 -40 -60

More info and screens

0

2. Health

2.1 Basic Checks

CYXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CYXT has been increased compared to 1 year ago.
CYXT has a worse debt/assets ratio than last year.
CYXT Yearly Shares OutstandingCYXT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 50M 100M 150M
CYXT Yearly Total Debt VS Total AssetsCYXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of -0.82, we must say that CYXT is in the distress zone and has some risk of bankruptcy.
CYXT has a Altman-Z score of -0.82. This is amonst the worse of the industry: CYXT underperforms 81.32% of its industry peers.
A Debt/Equity ratio of 31.18 is on the high side and indicates that CYXT has dependencies on debt financing.
With a Debt to Equity ratio value of 31.18, CYXT is not doing good in the industry: 81.32% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 31.18
Debt/FCF N/A
Altman-Z -0.82
ROIC/WACCN/A
WACC1.73%
CYXT Yearly LT Debt VS Equity VS FCFCYXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 500M 1B 1.5B 2B

2.3 Liquidity

CYXT has a Current Ratio of 0.43. This is a bad value and indicates that CYXT is not financially healthy enough and could expect problems in meeting its short term obligations.
CYXT has a worse Current ratio (0.43) than 90.11% of its industry peers.
A Quick Ratio of 0.43 indicates that CYXT may have some problems paying its short term obligations.
The Quick ratio of CYXT (0.43) is worse than 89.01% of its industry peers.
Industry RankSector Rank
Current Ratio 0.43
Quick Ratio 0.43
CYXT Yearly Current Assets VS Current LiabilitesCYXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

CYXT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.83%.
CYXT shows a small growth in Revenue. In the last year, the Revenue has grown by 6.60%.
Measured over the past years, CYXT shows a small growth in Revenue. The Revenue has been growing by 3.21% on average per year.
EPS 1Y (TTM)-19.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.04%
Revenue 1Y (TTM)6.6%
Revenue growth 3Y3.21%
Revenue growth 5YN/A
Sales Q2Q%7.84%

3.2 Future

The Earnings Per Share is expected to grow by 9.65% on average over the next years. This is quite good.
Based on estimates for the next years, CYXT will show a small growth in Revenue. The Revenue will grow by 4.62% on average per year.
EPS Next Y8.38%
EPS Next 2Y9.18%
EPS Next 3Y9.65%
EPS Next 5YN/A
Revenue Next Year5%
Revenue Next 2Y4.78%
Revenue Next 3Y5.1%
Revenue Next 5Y4.62%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CYXT Yearly Revenue VS EstimatesCYXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
CYXT Yearly EPS VS EstimatesCYXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYXT. In the last year negative earnings were reported.
Also next year CYXT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYXT Price Earnings VS Forward Price EarningsCYXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CYXT indicates a somewhat cheap valuation: CYXT is cheaper than 73.63% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.15
CYXT Per share dataCYXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.18%
EPS Next 3Y9.65%

More info and screens

0

5. Dividend

5.1 Amount

CYXT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYXTERA TECHNOLOGIES INC

NASDAQ:CYXT (6/14/2023, 9:24:44 PM)

After market: 0.0595 -0.01 (-8.46%)

0.065

+0.02 (+55.5%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)05-04 2023-05-04/bmo
Earnings (Next)08-09 2023-08-09/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners1.64%
Ins Owner Change0%
Market Cap11.68M
Analysts74.55
Price Target1.34 (1961.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.6%
Min EPS beat(2)-25.49%
Max EPS beat(2)50.7%
EPS beat(4)1
Avg EPS beat(4)-12.29%
Min EPS beat(4)-42.11%
Max EPS beat(4)50.7%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.79%
Min Revenue beat(2)-0.95%
Max Revenue beat(2)-0.63%
Revenue beat(4)0
Avg Revenue beat(4)-1.57%
Min Revenue beat(4)-2.44%
Max Revenue beat(4)-0.63%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-53.95%
PT rev (3m)-73.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-44.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF 0.12
P/B 0.18
P/tB N/A
EV/EBITDA 10.15
EPS(TTM)-1.16
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)0.55
OCFY842.51%
SpS4.23
BVpS0.36
TBVpS-3.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.37%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.68%
GM growth 5YN/A
F-Score4
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 31.18
Debt/FCF N/A
Debt/EBITDA 10.41
Cap/Depr 55.21%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.43
Quick Ratio 0.43
Altman-Z -0.82
F-Score4
WACC1.73%
ROIC/WACCN/A
Cap/Depr(3y)40.78%
Cap/Depr(5y)40.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.04%
EPS Next Y8.38%
EPS Next 2Y9.18%
EPS Next 3Y9.65%
EPS Next 5YN/A
Revenue 1Y (TTM)6.6%
Revenue growth 3Y3.21%
Revenue growth 5YN/A
Sales Q2Q%7.84%
Revenue Next Year5%
Revenue Next 2Y4.78%
Revenue Next 3Y5.1%
Revenue Next 5Y4.62%
EBIT growth 1Y-6.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year667.96%
EBIT Next 3Y107.59%
EBIT Next 5Y61.88%
FCF growth 1Y33.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y277.52%
OCF growth 3YN/A
OCF growth 5YN/A